4.4 Article

Genetics of HDL-C: A Causal Link to Atherosclerosis?

Journal

CURRENT ATHEROSCLEROSIS REPORTS
Volume 15, Issue 6, Pages -

Publisher

CURRENT MEDICINE GROUP
DOI: 10.1007/s11883-013-0326-8

Keywords

HDL cholesterol; Genetics; Cardiovascular disease; Atherosclerosis; Mendelian randomization; Genome-wide association; Apolipoprotein A-I; ATP-binding cassette transporter A1; Lecithin-cholesterol acyltransferase; Phospholipid transfer protein; Cholesteryl ester transport protein; Scavenger receptor class B type 1; Endothelial lipase

Funding

  1. AstraZeneca
  2. Aegerion
  3. Genzyme
  4. Isis Pharmaceuticals
  5. Roche
  6. Pfizer
  7. Eli Lilly
  8. MSD
  9. Cerenis

Ask authors/readers for more resources

Prospective epidemiological studies have consistently reported an inverse association between HDL cholesterol (HDL-C) levels and the risk of cardiovascular disease (CVD). However, large intervention trials on HDL-C-increasing drugs and recent Mendelian randomization studies have questioned a causal relationship between HDL-C and atherosclerosis. HDL-C levels have been shown to be highly heritable, and the combination of HDL-C-associated SNPs in recent large-scale genome-wide association studies (GWAS) only explains a small proportion of this heritability. As a large part of our current understanding of HDL metabolism comes from genetic studies, further insights in this research field may aid us in elucidating HDL functionality in relation to CVD risk. In this review we focus on the question of whether genetically defined HDL-C levels are associated with risk of atherosclerosis. We also discuss the latest insights for HDL-C-associated genes and recent GWAS data.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available